Institutional members access full text with Ovid®

Share this article on:

Novel antibiotic treatment for skin and soft tissue infection

Dryden, Matthew S.

Current Opinion in Infectious Diseases: April 2014 - Volume 27 - Issue 2 - p 116–124
doi: 10.1097/QCO.0000000000000050
SKIN AND SOFT TISSUE INFECTIONS: Edited by Matthew S. Dryden

Purpose of review Acute bacterial skin and skin structure infection (ABSSSI) is a common and significant indication for antibiotic treatment. The microbial aetiology is becoming more resistant to available antibiotics and the treatment of patients is additionally challenged by extremes of age, obesity, diabetes and other co-morbidities. This review examines recent antimicrobial developments.

Recent findings In many parts of the world, multidrug-resistant (MDR) staphylococci are the predominant cause of ABSSSI in both the community and in hospital. Increasing resistance in Gram-negative organisms presents problems in the management of surgical-site infections. Most new antibiotics have been developed to treat MDR Gram-positive bacteria and there are few agents to treat infections caused by MDR Gram-negative pathogens.

Summary A number of novel agents are available clinically, with other agents of related chemical structure under development. There are no entirely new classes of antibiotics. Maintaining the efficacy of antimicrobial treatment require effective antibiotic stewardship, good infection prevention and the development of further new antibiotics.

Hampshire Hospitals NHS Foundation Trust, Winchester, UK

Correspondence to Matthew S. Dryden, Hampshire Hospitals NHS Foundation Trust, Winchester SO22 5DG, UK. Tel: +44 1962863535; fax: +44 1962825431; e-mail: matthew.dryden@hhft.nhs.uk

© 2014 Lippincott Williams & Wilkins, Inc.